CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 87 target
Drug / intervention
Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumabdrug
Likely dose
Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05163483
NCT05163483Phase 2Unknown
CompareCT.gov

Tucidinostat in Combination With PD-1 Inhibitor and Bevacizumab as Late-line Treatment in Patients With Advanced Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction and Gastric Adenocarcinoma

Ruihua Xu·interventional·Posted Dec 20, 2021·Updated Mar 6, 2023

In Brief

A Phase 2 clinical trial evaluating Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab for Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma. Targeting 87 participants across 1 site.

Detailed Summary

This Phase II study was designed to assess the efficacy and safety of the combination of PD-1 inhibitor, Tucidinostat (chidamide), a histone deacetylase inhibitor, and bevacizumab in advanced Esophageal squamous cell cancer, adenocarcinoma of esophagogastric junction, Gastric adenocarcinoma patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
20222023202420252026
First PostedDec 20, 2021
Enrollment StartJul 1, 2022
Primary CompletionDec 1, 2023
Study CompletionDec 1, 2025
TodayJul 1, 2026
Enrollment to primary: 1.4 yearsPosted 4.5 years ago

Interventions

Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumabdrug

Tucidinostat (chidamide), 30mg, po., biw, q3w Toripalimab, 240mg, ivgtt., d1, q3w Bevacizumab, 7.5mg/kg, ivgtt., d1, q3w approximately 2 years